Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
228
resultados
Última actualización
24/04/2025 [06:52:00]
Resultados 25 a 50 de 228
Resumen de: WO2025080770A1
Methods are disclosed for increasing retinal ganglion cell (RGC) survival and/or RGC axon regeneration and/or optic nerve survival and/or optic never regeneration in a subject in need thereof. These methods include locally administering to an eye of the subject a therapeutically effective amount of (a) isolated nanovesicles derived from an extracellular matrix and (b) a statin or a pharmaceutically acceptable salt thereof. Combination therapy is also disclosed for use in increasing RGC survival and/or RGC axon regeneration and/or or optic nerve survival and/or optic nerve regeneration in a subject. Disclosed is therapeutically effective amount of (a) isolated nanovesicles derived from an extracellular matrix and (b) a statin or a pharmaceutically acceptable salt thereof, for use in increasing RGC survival, RGC axon regeneration and/or optic nerve survival and/or optic never regeneration in a subject in need thereof in a subject, wherein the isolated nanovesicles and the statin are formulated for ophthalmic administration.
Resumen de: WO2025080869A1
Drug delivery nanoparticle compositions and methods for the treatment of a cancer are provided that can be used individually or in combination. These compositions and methods include: (1) exogenous vaccination using neoantigens or tumor-associated antigens to potentiate an anti-tumor immune response; (2) nanoparticle-based drug delivery targeting the liver, aimed at reprogramming the hepatic immune environment to reduce or eliminate tumor antigen tolerance, thereby enhancing the immune system's ability to combat metastatic cancer; and (3) expansion of the liver metastasis treatment platform to target tumor-associated lymphoid structures, supporting the immune response at the primary tumor site. Any of these methods may be optionally combined with chemo-immunotherapy for enhanced efficacy.
Resumen de: WO2025080555A1
In one aspect, the present disclosure relates to certain ionizable lipid compounds and methods of preparation thereof. In another aspect, the present disclosure relates to lipid nanoparticles (LNPs) comprising certain ionizable lipid compounds of the present disclosure and methods of use thereof.
Resumen de: WO2025079599A1
The present invention addresses the problem of providing: a carrier that allows selective delivery thereof to a cell at a subset level, which cannot be realized by a conventional technique; and a method for producing said carrier. The present invention relates to: a carrier for realizing selective delivery thereof to a target cell having a plurality of target receptors on a surface thereof, wherein the carrier has individual ligands that respectively bind to the plurality of receptors, and is incorporated into target cells having all of the plurality of receptors, but not into cells that do not have at least one of the plurality of receptors; and a method for producing said carrier.
Resumen de: WO2025079114A1
A self-nano emulsifying drug formulation for cholecalciferol by a method of spontaneous emulsification and spray drying, the self-nano 5 emulsifying drug formulation for cholecalciferol comprising of one active ingredient cholecalciferol, powder substrates, oil phases, surfactants and co-surfactants, wherein, the active ingredient having a loading capacity range from 100 IU/g to 10,00,000 IU/g and has an increased rate of dissolution, increased rate of permeability and increased bioavailability of the at least one active ingredient, wherein, the method for adsorption of the self-nano emulsifying drug on the substrate to obtain a powder formulation is spontaneous emulsification and spray drying method (SESDM) where the homogenous mixture of self-nano emulsifying drug and the aqueous dispersion of solid substrate is prepared and atomized into fine droplets and kept in a drying chamber for rapid evaporation of liquid to form a powder formulation.
Resumen de: WO2025081106A2
Disclosed herein are protein-based compositions and conjugates thereof that can take advantage of beneficial delivery properties to improve vaccine efficacy. An example protein-based composition includes an albumin-binding nanobody and a peptide antigen domain. An example conjugate includes the protein-based composition attached to a drug through a linker. Also disclosed are methods of making and using the protein-based compositions and conjugates thereof.
Resumen de: MX2024000327A
The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.
Resumen de: WO2025081194A2
Antigen-presenting nanoparticles and methods of engineering CAR T cells and treating and/or preventing cancer using the same.
Resumen de: MX2024012714A
Methods and compositions for cellular rejuvenation of immune cells, such as T cells, are provided. Cellular rejuvenation can be achieved by exposure, such as transient exposure, of immune cells to mRNAs encoding reprogramming factors. Compositions comprising such rejuvenated immune cells, including rejuvenated T cells, and uses of the rejuvenated immune cells in treating certain diseases and/or disorders, such as cancer and immune disorders, are also provided
Resumen de: CN119032086A
The present invention relates to novel sulfide-containing ionizable lipids. When the lipid nanoparticles are generated, the ionizable lipid according to the present invention enables the drug to be efficiently encapsulated in the lipid nanoparticles and enables the drug to be stably delivered into the body by electrostatically interacting with the anionic drug, thereby improving the bioavailability of the drug. Therefore, the method can be effectively applied to the related fields such as lipid nanoparticle mediated gene therapy and the like.
Resumen de: AU2023254203A1
The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction with an LNP-encapsulated CRISPR/Cas9 gene editing system.
Resumen de: US2025115715A1
Provided are a polymer compound and a composition for nucleic acid delivery comprising the same, wherein the polymer compound has a high binding affinity to nucleic acids and effectively protects nucleic acids from nucleases, thereby improving the nucleic acid delivery effect and stability.
Resumen de: US2025120928A1
The present disclosure provides polymer-drug conjugates comprising suberoylanilide hydroxamic acid (SAHA), derivatives thereof, and salts thereof. The disclosure further provides nanoparticles comprising the polymer-drug conjugate. The disclosure provides methods of treating a disease or disorder in a subject by administering the conjugate or a plurality of nanoparticles comprising the conjugate to the subject. In some embodiments, the disease or disorder is sepsis, septic shock, hemorrhagic shock, or poly-trauma.
Resumen de: US2025120912A1
Synergistic nanomedicine delivering topoisomerase I toxin (SN-38) and inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for enhanced treatment of colorectal cancer
Resumen de: US2025120914A1
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Resumen de: US2025120904A1
A method and apparatus for the targeted delivery of chemotherapy to a surgical cavity, consisting of a triggered nanoparticle encapsulating a therapeutic agent and an energy delivery device that applied trigger energy to the surgical cavity. Following surgical removal of a cancerous tumor, the nanoparticle is administered, and the energy delivery device applies trigger energy to the surgical cavity and proximal tissue. The goal is the delivery of a therapeutic drug dose to cancerous and precancerous cells remaining after surgery, to prevent local tumor recurrence.
Resumen de: US2025122247A1
The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
Resumen de: US2025121052A1
Disclosed herein are vaccine compositions that include SARS-CoV-2 MHC epitope-encoding cassettes and/or full-length SARS-CoV-2 proteins. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.
Resumen de: US2025121098A1
The present invention provides nanoparticles or conjugates comprising at least one ligand that selectively targets major facilitator superfamily domain-containing protein-2a (MFSD2A). In various embodiments, the nanoparticles or conjugates of the invention target at least one cell comprising MFSD2A (e.g., endothelial cells of blood brain barrier). In some embodiments, the nanoparticles or conjugates of the invention cross the blood brain barrier and/or blood retinal barrier. In other aspects, the present invention relates to methods for in vivo delivery of diagnostic and/or therapeutic agents to a brain. In other aspects, the present invention relates to methods of preventing or treating a neurological or cognitive disease or disorder using the nanoparticles or conjugates of the invention.
Resumen de: US2025121043A1
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
Resumen de: US2025120997A1
Disclosed herein is a composition including a nucleoside-modified mRNA encapsulated in a lipid nanoparticle wherein the nucleoside-modified mRNA encodes IL10, IL-6, MIP1a, GDNF (glial cell line-derived neurotrophic factor), or a combination thereof. A method of treated spinal cord injury is also described.
Resumen de: US2025120916A1
The instant disclosure teaches a highly efficient cellulose-based nanoadsorbent that can capture more than 6000 mg of doxorubicin (DOX), one of the most widely used chemotherapy drugs, per gram of the adsorbent at physiological conditions. Such drug capture capacity is more than 3200% higher than other nanoadsorbents, such as DNA-based platforms. The disclosure teaches how anionic hairy cellulose nanocrystals, also known as electrosterically stabilized nanocrystalline cellulose (ENCC), bind to positively charged drugs in human serum and capture DOX immediately without imposing any cytotoxicity and hemolytic effects. The disclosure further elucidates how ENCC provides a remarkable platform for biodetoxification at varying pH, ionic strength, ion type, and protein concentration. These discoveries pave the way for the next generation in vitro and in vivo drug capture additives and devices.
Resumen de: US2025120913A1
A pharmaceutical composition of Quercetin nanosuspension comprising Quercetin dihydrate, about 0.1% w/w to 10% w/w of Poloxamer, about 0.1% w/w to 10% w/w of polyvinyl pyrrolidone, and about 0.1% w/w to 10% w/w of polyethylene glycol. A method for preparing Quercetin nanosuspension, comprising the steps of dissolving polyvinyl pyrrolidone, Poloxamer, and polyethylene glycol in purified water, adding Quercetin to the above solution, subjecting the resulting mixture to bead milling to form Quercetin nanocrystals or nanosuspension.
Resumen de: US2025121079A1
This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.
Nº publicación: AU2023357320A1 17/04/2025
Solicitante:
BIONTECH SE
BIONTECH SE
Resumen de: AU2023357320A1
The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g., but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g., in combination with a chemotherapeutic agent). The present disclosure further provides RNA backbones containing specific sequences upstream and/or downstream from the coding sequence.
BOPI
Sede Electrónica
